Overview of Peptides: The Science, Uses & Safety | Dr. Abud Bakri
This episode is a deep dive into the rapidly expanding world of peptides, with a focus on how to classify them, what is actually known about their effects, and where the safety and regulatory concerns lie. Andrew Huberman and Dr. Abud Bakri break peptides into broad functional groups: FDA-approved receptor-targeting peptides like GLP-1 drugs, and more experimental peptides with unclear or unknown receptors, many of which are backed mostly by animal studies and anecdotal reports. The conversation centers on commonly discussed compounds such as BPC-157, pinealon/epitalon, thymic peptides, GHK-Cu, growth hormone secretagogues, and GLP-1s, while repeatedly emphasizing the gap between exciting claims and solid human evidence.
Main Themes and Framework
How Dr. Bakri categorizes peptides
- Peptides are described as one of the body’s “languages” for cell-to-cell communication.
- A key distinction is:
- Peptides with known receptors: e.g. GLP-1 drugs.
- Peptides without clearly identified receptors: e.g. BPC-157, TB-500/TB-4, many Russian bioregulators.
- This receptor distinction is important because it strongly affects how confidently clinicians can predict effects and risks.
Evidence hierarchy matters
- Much of the peptide enthusiasm comes from:
- animal data
- small or incomplete human trials
- anecdotal reports
- Dr. Bakri repeatedly stresses that many peptides are promising, but still lack robust, large-scale human validation.
Key Peptides Discussed
BPC-157
- Originally derived from gastric-related research and thought to be a gut-protective compound.
- In animals, it has shown effects related to:
- tendon and ligament repair
- wound healing
- nerve repair
- gut protection
- stress resilience
- Mechanistically, it may influence:
- VEGF/angiogenesis
- nitric oxide signaling
- cell migration
- growth factor signaling
- the gut-brain axis
- Safety concerns remain unresolved:
- no clear LD50 in humans
- mostly one research group’s data
- uncertain systemic behavior and bioavailability
- theoretical concerns about promoting blood vessel growth in unwanted places
- Human evidence is very limited:
- small rectal/enema studies for ulcerative colitis
- incomplete published data
- Dr. Bakri’s stance: promising, but not ready for broad medical endorsement.
Pinealon / Epitalon / “EDR”
- These Soviet-era bioregulator peptides are presented as aging/circadian/brain-supportive compounds.
- Dr. Bakri distinguishes:
- epitalon: linked to pineal-related work
- pinealon: often confused with epitalon, but described as a cortex-derived tripeptide
- Reported or proposed effects include:
- improved circadian rhythm
- increased REM sleep
- better daytime cognition
- reduced brain fog
- possible DNA repair/longevity signaling
- He notes that his own and others’ anecdotal experiences suggest:
- morning use may be better than bedtime use
- some people get vivid dreams or altered sleep architecture
- Risks:
- blood sugar lowering
- vivid dreams/nightmares
- uncertain generalizability because most evidence comes from Russian literature
Thymus-related peptides: Thymosin Alpha-1, Thymosin Beta-4, Thymulin
- The thymus is framed as a major but underappreciated organ involved in immune training and immune aging.
- Important ideas:
- thymic function declines after puberty
- lower thymic function is associated with aging, autoimmunity, infections, and mortality risk
- thymic size/function may be modifiable
- Thymosin Alpha-1
- immunomodulatory
- discussed as something people use for immune support, travel, or recovery
- has had uses in certain countries and specific medical contexts
- Thymosin Beta-4 / TB-500
- associated with repair and actin/cytoskeleton dynamics
- popular in performance and doping circles
- Thymulin
- zinc-dependent thymic peptide
- may support immune function and interact with hormone axes
- Dr. Bakri is especially interested in thymic health as a marker of immune aging.
GHK-Cu
- A copper-containing tripeptide linked to collagen, skin, hair, and tissue remodeling.
- Commonly discussed in aesthetics and “glow”/skin protocols.
- Potential uses:
- topical skin repair
- photoaging support
- hair/skin/collagen support
- Human evidence exists more than for some other peptides, especially topically.
- Less convincing as a hair-loss treatment than as an adjunctive skin-care peptide.
- Injection is more controversial than topical use.
Growth hormone secretagogues and related compounds
- Includes:
- tesamorelin
- ipamorelin
- MK-677 (not a peptide, but discussed in the same ecosystem)
- Purpose:
- increase growth hormone/IGF-1 indirectly
- Possible effects:
- more muscle and recovery
- better sleep architecture in some people
- improved body composition
- Concerns:
- increased hunger
- insulin resistance
- possible impacts on prostate size
- uncertainty about long-term cancer risk or aging tradeoffs
- He describes a broader “somatopause” idea: growth hormone tends to decline with age, but whether replacing it is beneficial long term is still debated.
GLP-1 drugs
- The episode treats GLP-1s as the best-established peptide class discussed:
- semaglutide
- tirzepatide
- retatrutide
- related obesity and diabetes therapies
- Benefits:
- strong weight loss
- improved insulin sensitivity
- major impact on obesity and diabetes management
- Concerns:
- nausea, vomiting, and GI side effects
- loss of motivation or general drive in some users
- under-eating, electrolyte issues, or malnutrition if misused
- uncertain long-term effects on developing brains and neuroplasticity
- He emphasizes that these drugs have changed medicine, but they must be used carefully and with monitoring.
Safety, Regulation, and Sourcing
The biggest risks are often not just the molecule itself
The conversation repeatedly stresses that harm can come from:
- contamination
- wrong compound in the vial
- poor dosing
- using peptides without medical supervision
- mixing peptides with other substances
- sourcing from unreliable “research only” markets
Market categories discussed
- Big pharma / FDA-approved: highest confidence in purity and dosing
- Compounding pharmacies: variable quality; some are very good, others less so
- Gray market: “for research purposes only,” highly variable, often untrustworthy
- Black market: direct-from-China or underground manufacturing, highest risk
Legal uncertainty
- The legal status of many peptides is described as fluid and state-dependent.
- Dr. Bakri notes that:
- some peptides moved into more restricted regulatory categories
- state medical boards may still differ from FDA-related guidance
- telehealth prescribing is complicated by state-specific rules
Practical Takeaways
What Dr. Bakri seems to support
- Peptides should be thought of as tools, not miracle substances.
- The best candidates for near-term clinical study may be:
- ulcerative colitis / gut repair with BPC-157
- musculoskeletal healing after surgery or injury
- immune aging and thymus-related outcomes
- circadian/brain-aging questions around epitalon/pinealon
- skin and collagen support with GHK-Cu
What he advises caution on
- Avoid assuming that animal data = proven human benefit.
- Avoid buying peptides from unregulated, research-only sources.
- Be careful with any peptide that alters:
- angiogenesis
- immune signaling
- glucose control
- appetite
- endocrine axes
- For most people, basics still matter most:
- sleep
- sunlight
- nutrition
- exercise
- stress management
Notable Insights
- BPC-157 may be less about “anti-inflammatory” effects and more about pushing repair pathways.
- The thymus may be a major but underused marker of aging and immune health.
- Peptide use is now normalized partly because GLP-1 injections made self-injection socially acceptable.
- Many “peptide protocols” are really emerging as lifestyle/status ecosystems, not just medicine.
- The field badly needs clearer naming conventions and better human trials.
Bottom Line
This episode presents peptides as a high-potential but highly uneven field: some compounds are established medicines with clear benefits, while many others remain intriguing but under-studied tools supported mostly by animal data and anecdote. Dr. Bakri’s core message is not that peptides are universally good or bad, but that they must be understood by mechanism, evidence quality, sourcing, and regulatory status. For now, the most important practical advice is to be skeptical of hype, prioritize medical supervision, and remember that the best-supported health interventions still start with the basics.